Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment
First Claim
1. A nutritional drink for oral consumption comprising:
- a unit dose sufficient to a) raise blood levels of D-β
-hydroxybutyrate to about 0.1 to about 5 mM or b) raise urinary excretion levels of D-β
-hydroxybutyrate to about 5 mg/dL to about 160 mg/dL;
L-camitine, a plurality of vitamins;
flavoring, and a carbohydrate source and wherein the MCT are of the formula;
wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having carbon chains of 5-12 carbons.
4 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal.
-
Citations
34 Claims
-
1. A nutritional drink for oral consumption comprising:
- a unit dose sufficient to a) raise blood levels of D-β
-hydroxybutyrate to about 0.1 to about 5 mM or b) raise urinary excretion levels of D-β
-hydroxybutyrate to about 5 mg/dL to about 160 mg/dL;
L-camitine, a plurality of vitamins;
flavoring, and a carbohydrate source and wherein the MCT are of the formula;wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having carbon chains of 5-12 carbons. - View Dependent Claims (2, 3, 4, 5, 6)
- a unit dose sufficient to a) raise blood levels of D-β
-
7. A method of treatment for Age-Associated Memory Impairment (AAMI), comprising administration comprising the steps of:
-
identifying a mammal having, or at risk of AAMI; and administering to the mammal a composition comprising at least one compound capable of elevating ketone body concentrations in an amount effective for the treatment of or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. - View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34)
-
-
33. A method for treatment of Age-Associated Memory Impairment (AAMI) comprising the steps of:
-
(a) identifying a population of healthy aging mammals having AAMI; (b) dividing the population into at least a control group and one or more test groups; (c) formulating at least one delivery system for delivering a composition comprising at least one compound capable of elevating ketone body concentrations in an amount effective for elevating at least one type of ketone body in the blood of an individual mammal; wherein, on an extended regular basis, each test group receives a formulation delivering a composition comprising at least one compound capable of elevating ketone body concentrations in an amount effective for elevating at least one type of ketone body in the blood of an individual mammal and the control group does not receive any composition comprising at least one compound capable of elevating ketone body concentrations in an amount effective for elevating at least one type of ketone body in the blood of an individual mammal; (d) comparing at least one neuropsychological test result in the control and test groups; (e) determining which of the delivery systems for delivering the composition comprising MCT was effective in improving the results of at least one neuropsychological test; and (f) administering a treatment-based delivery system determined in step (e) to a population of aging mammals, thereby treating AAMI.
-
Specification